- Home
- WPP vs PTCT Comparison
WPP vs PTCT Comparison
Compare WPP & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WPP
- PTCT
- Stock Information
- Founded
- WPP 1985
- PTCT 1998
- Country
- WPP United Kingdom
- PTCT United States
- Employees
- WPP N/A
- PTCT N/A
- Industry
- WPP Advertising
- PTCT Biotechnology: Pharmaceutical Preparations
- Sector
- WPP Consumer Discretionary
- PTCT Health Care
- Exchange
- WPP Nasdaq
- PTCT Nasdaq
- Market Cap
- WPP 5.9B
- PTCT 4.8B
- IPO Year
- WPP N/A
- PTCT 2013
- Fundamental
- Price
- WPP $24.83
- PTCT $65.58
- Analyst Decision
- WPP Sell
- PTCT Buy
- Analyst Count
- WPP 1
- PTCT 14
- Target Price
- WPP N/A
- PTCT $67.00
- AVG Volume (30 Days)
- WPP 453.3K
- PTCT 1.3M
- Earning Date
- WPP 08-07-2025
- PTCT 11-06-2025
- Dividend Yield
- WPP 10.48%
- PTCT N/A
- EPS Growth
- WPP 86.47
- PTCT N/A
- EPS
- WPP 0.47
- PTCT 7.72
- Revenue
- WPP $19,423,208,660.00
- PTCT $1,764,929,000.00
- Revenue This Year
- WPP N/A
- PTCT $119.89
- Revenue Next Year
- WPP N/A
- PTCT N/A
- P/E Ratio
- WPP $10.24
- PTCT $8.47
- Revenue Growth
- WPP N/A
- PTCT 96.00
- 52 Week Low
- WPP $23.43
- PTCT $34.57
- 52 Week High
- WPP $57.37
- PTCT $67.40
- Technical
- Relative Strength Index (RSI)
- WPP 44.38
- PTCT 71.17
- Support Level
- WPP $24.10
- PTCT $57.74
- Resistance Level
- WPP $25.40
- PTCT $67.40
- Average True Range (ATR)
- WPP 0.50
- PTCT 2.26
- MACD
- WPP 0.07
- PTCT 0.20
- Stochastic Oscillator
- WPP 41.09
- PTCT 80.75
About WPP WPP plc
Headquartered in the United Kingdom, WPP is the world's largest ad holding company based on annual revenue. Its services, which include traditional and digital advertising, public relations, and consulting, are provided worldwide, with over 70% of its revenue coming from more developed regions such as North America, the UK, and Western Europe. WPP is the largest media buying entity in the world.
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.